This article is more than 5 years old. Information may no longer be current.

Health Canada approves CINGAL as medical device to treat knee OA pain

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Anika Therapeutics Inc. recently announced Health Canada approval of CINGAL as a medical device to treat pain due to osteoarthritis of the knee.

According to a company press release, this is the first regulatory approval for this next-generation viscosupplement.

The device is the only approved combination viscosupplement. It is formulated with a proprietary cross-linked sodium hyaluronate — the proprietary hyaluronate in Anika’s single-injection viscosupplement MONOVISC — and with triamcinolone hexacetonide, which is a steroid that is FDA-approved to treat inflammation, according to the press release.

The CINGAL device is a third-generation viscosupplementation product from Anika Therapeutics for the treatment of joint pain associated with osteoarthritis.

Reference: www.anikatherapeutics.com